Ehave Expands Its Psychedelic Mental Health Platform with Medchart, a Leader in Medical Record Software, as a Plugin to the Ehave Dashboard

Ehave Expands Its Psychedelic Mental Health Platform with Medchart, a Leader in Medical Record Software, as a Plugin to the Ehave Dashboard

Ehave partners with world-renowned tech platform, Medchart. The Medchart plugin will allow medical professionals using the Ehave Dashboard to easily transfer medical records, while allowing patients to own their own data and do what they want with it.

MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced today it has added Medchart, the only comprehensive solution for medical record exchange, as the first plugin to its Ehave Dashboard. This will not only allow patients to take more control over their psychedelic medical records, it will allow patients to access innovative treatments to mental health by providing clinicians and pharmaceutical companies with data that will make the provision of care more readily available. The combination of Medchart with the Ehave Dashboard will help provide a dataset that can be used to clinically validate some of these more experimental forms of therapy including psychedelics and ketamine treatment.

Personal Health Records (PHR) are a patient’s individualized collection of their health records. By allowing patients to own their own records, medical professionals and psychedelic researchers can begin working with patients to create biomarkers on the how they can live a longer healthier life, as well as what treatments are effective. Giving data to the PHR helps doctors who can prescribe medicine based on your data. As you add sensors into the dashboard you can add more data in your PHR. There are 11 million Americans who are resistant to most mental health therapies, and they can cost the healthcare system as much as $250 billion. Since major pharmaceutical companies don’t develop drugs for them, the Ehave Dashboard could potentially aggregate data from this patient population and provide that data to drug developers for clinical trials. This data could also help insurers route patients to the treatment providers who can help them the most.

Toronto-based Medchart, which enables the electronic transfer of medical records through express patient consent, simplifies the request of health information for patients. Medchart digitizes the exchange of health information between healthcare providers, attorneys, insurers, payers, researchers and patients while improving transfer speed, data quality, and business insights through artificial intelligence and machine learning. The company provides cloud based medical record solutions across North America with purpose-built solutions for personal injury and mass tort attorneys in the United States. Medchart complies with all federal and provincial privacy legislation including HIPAA, PIPEDA, PHIPA, PIPA, PHIA, HIA, and more.

The Ehave Dashboard is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals, The Hospital for Sick Children in Ontario. In addition to providing better outcomes, the proprietary platform allows individuals to take control of their physical and mental health by enabling them to carry their medical records with them wherever they go. As a result of a strategic partnership with BurstIQ to further develop the blockchain capabilities of its platform, the Ehave Dashboard has the ability to segment data on-chain, which will allow developers, clinicians, researchers, doctors, hospitals, universities and, ultimately, prescribers of Psychedelic therapy, to provide life-changing solutions to patients. BurstIQ is a HIPAA and GDPR compliant global data platform, and the industry’s only Big Data blockchain that keeps data on chain and safe in the cloud.

“The combination of a Blockchain plugin and an Artificial intelligence plugin has enabled us to build the most trusted and analytical platform to collect, analyze, and give doctors and mental health professionals a platform to heal,” said Alfred Farrington II, CIO of Ehave. Mr. Farrington continued, “It also provides a dataset that can be used to clinically validate some of these more experimental forms of therapy including psychedelics and ketamine treatment.”

Ben Kaplan, CEO of Ehave, said, “Plugin-based software systems are the next step of evolution in application development. Plugin frameworks enable users to easily enhance existing applications more conveniently. Not only will the addition of the Medchart plugin enhance the experience of our Ehave Dashboard users, Ehave will save a tremendous amount of development time, which in turn will save on our overall budget.” Mr. Kaplan continued, “The addition of the Medchart platform in our Ehave dashboard will be well received by the healthcare professionals and psychedelic research teams using the Ehave Dashboard.”

Additional Ehave Inc. Statement

We are truly grateful for the patience and support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company diligently posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.

About Medchart

Medchart digitizes the exchange of health information between healthcare providers, attorneys, insurers, payers, researchers and patients while improving transfer speed, data quality, and business insights through artificial intelligence and machine learning. The company provides cloud based medical record solutions across North America with purpose-built solutions for personal injury and mass tort attorneys in the United States.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, https://www.sec.gov.

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046

Email: erelationsgroup@gmail.com